Foamix Fortifies its Patent Position in Mexico

Top Quote Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, announced today that the Company has obtained another granted patent in Mexico. End Quote
  • (1888PressRelease) June 04, 2012 - As of today Foamix has four granted patents in Mexico:

    MX Patent No.277933 entitled"Foam Incorporating Eutectic Mixture ";
    MX Patent No.268451 entitled"Cosmetic And Pharmaceutical Foam ";
    MX Patent No.282498 entitled"Oleaginous Pharmaceutical And Cosmetic Foam "; and
    MX Patent No.287254 entitled"Saccharide Foamable Compositions".

    Additionally, a notice of allowance has been received for another of Foamix's MX Patent applications.

    These patents relate to several different platform foam technologies developed by Foamix and describe unique foam formulations and their uses in topical therapy.

    "Mexico is an important country and these new achievements fortify Foamix's patent position and offer greater protection for existing and potential partners of the company ," remarks Dr. Dov Tamarkin, CEO of Foamix. "We are pleased that Mexico's Patent Office and other Patent Offices around the world continue to recognize Foamix's innovation in the field of topical foams ."
    About Foamix

    Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams and OilGel™ products for dermatology, gynecology, wounds and burn applications, as well as ophthalmic disorders. Foamix collaborates with leading pharmaceutical companies in the creation of advanced products with improved convenience, higher compliance and better efficacy, which are backed by an extensive patent portfolio.
    The Company's development capabilities range from initial development of the formulations to scale-up, GMP manufacturing, preclinical and clinical studies.

    Foamix has a strong in-house pipeline. The Company's lead product, Topical Minocycline, is currently in Phase II clinical studies.

    To date, Foamix has 13 issued patents in the United States and 54 granted patents worldwide, covering its foam and OilGel™ technology platforms. Additionally, the company has more than 120 pending patent applications worldwide, of which over 60 applications are filed in the U.S.

    For additional information please
    Contact: Dov Tamarkin, CEO, Foamix Ltd.,dov ( @ ) foamix dot co dot il dot
    Dorit Hayon, Business Development Manager, Foamix Ltd.,dorit ( @ ) foamix dot

  • FB Icon Twitter Icon In-Icon
Contact Information